


Excellent Long Term Safety and Efficacy⁴

Sustained safety and efficacy for at least 3 years in 5400 real-world patients⁵




A very large international prospective registry² of the BioMatrix[™] Family of stents in unselected patients demonstrates:

- ✓ Low cardiac death rate at 3 years (2.1%)
- ✓ Low myocardial infarction rate at 3 years (3.2%)
- ✓ Low target vessel revascularization rate at 3 years (5.6%)
- ✓ Low composite MACE rate at 3 years (9%)


* MACE: A Composite of cardiac death, MI, or clinically indicated TVR

Superior long term outcomes in complex real-world patients^{6,7,8}




POCE: Composition of all death, all MI, all revascularization
MACE: Composite of cardiac death, MI (target vessel MI in COMFORTABLE AMI study), c-TVR
c-TVR: Clinically indicated Target Vessel Revascularization
CD: Cardiac Death
STEMI: ST-elevated Myocardial Infarction
IDDM: Insulin-dependent Diabetes Mellitus
CTO: Chronic Total Occlusion
RRR: Relative Risk Reduction

Lowest very late stent thrombosis in all-comer trials⁹



Rates of very late definite stent thrombosis in all-comers randomized trials comparing DES at 3 years of follow-up⁹

Over 20'300 patients have been treated with BioMatrix Family stents in various randomized controlled trials



BIOMATRIX[®] alpha
DRUG ELUTING CORONARY STENT SYSTEM

Power to Heal

Ordering Information

Stent Diameter (mm)	Stent Length (mm)						
	9	14	19	24	29	33	36
2.25	BMX6-2209	BMX6-2214	BMX6-2219	BMX6-2224	BMX6-2229		
2.50	BMX6-2509	BMX6-2514	BMX6-2519	BMX6-2524	BMX6-2529	BMX6-2533	BMX6-2536
2.75	BMX6-2709	BMX6-2714	BMX6-2719	BMX6-2724	BMX6-2729	BMX6-2733	BMX6-2736
3.00	BMX6-3009	BMX6-3014	BMX6-3019	BMX6-3024	BMX6-3029	BMX6-3033	BMX6-3036
3.50	BMX6-3509	BMX6-3514	BMX6-3519	BMX6-3524	BMX6-3529	BMX6-3533	BMX6-3536
4.00	BMX6-4009	BMX6-4014	BMX6-4019	BMX6-4024	BMX6-4029		

1. Biosensors International internal bench testing performed on 3.0 mm stents. Data on file at Biosensors International
2. Percentage change in stent length after applying 5N compression force longitudinally
3. Recoil measured as percentage change in diameter at RBP
4. This data is related to BioMatrix Family, which has the exact same coating and equivalent pharmacokinetics as BioMatrix Alpha
5. Hildick-Smith D et al. EuroPCR 2015
6. Windecker S et al. Lancet. 2008; 372:1163-73
7. Serruys PW, et al. JACC Cardiovasc Interv. 2013; 6:777-89
8. Räber L, et al. Circ Cardiovasc Interv. 2014; 7:355-64
9. Stefanini G, Windecker S. Circulation Card Intv 2012; 5:332-5
10. De Cock D, et al. Cardiovascular Imaging. 2014; 15:900-09
11. Lüscher TF, et al. Circulation. 2007; 115:1051-58
12. Farb A, et al. Circulation. 2003; 108:1701-06
13. Joner M, et al. J Am Coll Cardiol. 2006; 48:193-202
14. Gladden LB. J Physiol. 2004; 558(1):5-30
15. Ghani, QP, et al. Methods in Enzymology. 2004; 381(36):565-75
16. Granada JF, SOLACI-CACI 2014



BioMatrix Alpha[™] drug eluting stent system is CE approved.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioMatrix NeoFlex, BioMatrix Flex, Juno, Quadrature Link, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. All cited trademarks are the property of their respective owners.

Not available for sale in the United States and certain other countries.
© 2016. Biosensors International Group, Ltd. All rights reserved.

www.biosensors.com



BIOSENSORS EUROPE SA
Rue de Lausanne 29
1110 Morges
Switzerland
Tel: +41 (0)21 804 80 00
Fax: +41 (0)21 804 80 01


BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD
36 Jalan Tukang
Singapore 619266
Tel: +65 6213 5777
Fax: +65 6213 5737

11362-000EN - Rev.03




BIOMATRIX[®] alpha
DRUG ELUTING CORONARY STENT SYSTEM

Power to Heal




BioMatrix Alpha™ Stent Platform
Simplifying all Complexities¹



BioMatrix Alpha™ Power to Heal


Biolimus A9™ Designed for Vascular Technology
Not All Limus Drugs are the Same

- ✓ 10 times more lipophilicity than Sirolimus
- ✓ Slower metabolism of drug due to its structure
- ✓ High local bioavailability



Specifically Designed Pro-Healing Polymer
Not All Polymers Are the Same

- ✓ Biosensors' PLA polymer degrades to naturally occurring Lactic Acid and Lactate
- ✓ Lactate plays a key role in local arterial wound healing processes, mainly via enhanced VEGF production^{14,15}




With the Same Abluminal BA9™ and PLA Coating Content, BioMatrix Alpha Has Similar BA9 Release Profile as Other BioMatrix Family Products

Best-in-Class Stent Platform Design¹ with Unique Pro-Healing Coating... from the Pioneer in Abluminal Biodegradable Technology

Alpha best-in-class performance vs. other stents¹


CELL OPENING

Large cell opening for easy side branch access




LONGITUDINAL COMPRESSION²

Lowest percentage change in length
High confidence when recrossing the stent




RECOIL³

Lowest percentage change in diameter to avoid malapposition




Designed to match the entire wound healing journey of real-world patients




- ✓ Every patient heals differently and it's not always possible to predict how long a particular patient will need anti-restenotic therapy
- ✓ Available data suggest that many DES-related lesions are likely to take more than 3 to 4 months to heal completely^{10, 11, 12, 13}
- ✓ BA9 release and PLA biodegradation is optimized to cover the entire period of arterial wound healing

Are other DES drug kinetics¹⁶ adequate to cover the arterial wound healing cascade?

SYNERGY™



ORSIRO™



ABSORB™ BVS

